CLINICAL_TRIALS
trial_result
· 2021-06-16
Clinical Trial Update: Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease [Phase 2]
Summary
Phase 2 trial update for vismodegib in steroid-refractory chronic graft-versus-host disease has been terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Graft Versus Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-06-16